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wAn 80-year-old woman was admitted with pulmonary
edema. She had a history of 2 prior sternotomies: a
coronary artery bypass grafting (CABG) plus aortic
valve replacement (AVR) with a 23-mm Medtronic-
Freestyle (Minneapolis, Minnesota) stentless biopros-
thesis 15 years ago, and a redo CABG 10 years ago.
Doppler echocardiography showed severe aortic xeno-
graft regurgitation (Figs. 1A and 1B, Online Videos 1,
, and 3). The patient was considered at very high risk
or re-AVR (third sternotomy, STS score: 10.7%, lo-
istical EuroSCORE: 26.3%) and was consequently
roposed for transcatheter aortic valve implantation
TAVI), therefore, a valve-in-valve procedure.
The TAVI procedure was performed by the trans-
emoral approach (1). Based on an aortic annulus
easured by transesophageal echocardiography
TEE) of 18.5 mm, a 23-mm Edwards-SAPIEN-XT
Edwards Lifesciences Inc., Irvine, California) was
elected for implantation (Figs. 1C to 1E). The
ajor challenge of the procedure was to position
he TAV within a stentless (no radio-opaque ring
r markers) bioprosthesis; indeed, TEE images
ere suboptimal to guide valve positioning. The
igtail catheter was therefore placed into the right
inus of Valsalva, and further used as a landmark to
osition about half of the stent valve prosthesis
elow and above the points of insertion of the
tentless xenograft leaflets as determined by fluo-
oscopy and angiography (Figs. 2A and 2B, Online
ideo 4). The TAV was deployed under rapid
acing using a very slow balloon inflation tech-
From the *Division of Interventional Cardiology, Quebec Heart & Lung
Institute, Laval University, Quebec City, Quebec, Canada, †Division of
Cardiovascular Surgery, Quebec Heart & Lung Institute, Laval Univer-
sity, Quebec City, Quebec, Canada; and the ‡Division of Anesthesia,
Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec,
Canada. Drs. Dumont and Rodés-Cabau are consultants for Edwards
Lifesciences Inc. The other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.3
Manuscript received May 9, 2011; revised manuscript received August 16,
2011, accepted September 14, 2011.ique that would permit some minor repositioning
efore full valve prosthesis expansion, and the
igtail catheter was left in place as a positioning
arker just until the TAV was about half deployed
Fig. 2C, Online Video 5). Angiographic and TEE
mages immediately after valve-in-valve implantation
howed the appropriate position of the prosthesis
ithout significant transprosthetic gradient, valvular
r paravalvular aortic regurgitation (Figs. 2D to 2F,
nline Videos 6 and 7). The post-procedural course
as uneventful, and the patient was discharged home
Figure 1. Transesophageal Echocardiography,
Balloon-Expandable Valve, and Delivery System
(A–B) Transesophageal echocardiography (long-axis view)
images showing complete left coronary leaﬂet (anatomic) pro-
lapse causing severe aortic xenograft regurgitation. (C) The
23-mm Edwards-SAPIEN-XT. (D) The 18-F NovaFlex delivery sys-
tem (Edwards Lifesciences) and (E) its ﬂuoroscopic aspect. Thin
arrows (A) highlight xenograft leaﬂet prolapse. For a better
appreciation, see also the Online Videos 1, 2, and 3.days after TAVI. Echocardiography at hospital
arkers)
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1249discharge showed a residual mean gradient of 13 mm Hg
(aortic valve area of 1.43 cm2). At 4-month follow-up, the
patient was in New York Heart Association functional class I.
The transcatheter valve-in-valve technique has opened a new
avenue for the treatment of failed xenografts placed in different
cardiac positions (2). However, the experience with the transcath-
eter treatment of dysfunctional stentless aortic valves has been
limited to a few cases using the self-expandable CoreValve system
(Medtronic) (3,4) or the balloon-expandable Edwards valve im-
planted by the transapical approach (2). The transapical, as
compared with the transfemoral approach, has been suggested as
the approach of choice for valve-in-valve cases performed with
balloon-expandable valves because of the greater stability provided
by a much shorter delivery system and potentially better coaxiality
with respect to the aortic annulus (2). This would reduce the
potential risks of valve malpositioning or embolization associated
with valve-in-valve procedures. Furthermore, although the labeled
size of the stentless valve in the present case was 23 mm, TEE
measurements showed an aortic-annulus of 18.5 mm, which
might have contraindicated the CoreValve system.
The present report shows the feasibility of a transfemoral
valve-in-valve procedure using a balloon-expandable valve for the
treatment of stentless aortic bioprosthesis dysfunction presenting
as severe valvular regurgitation. This case also suggests that the use
of an additional marker, such as the pigtail catheter, and a very
Figure 2. Transcatheter Valve-in-Valve Procedure Using Slow Balloon Inflat
(A) Fluoroscopy showing the pigtail catheter used as a landmark to position the b
opaque markers) xenograft. (B) Aortography with the TAV about half below and a
tion. (C) Slow balloon inﬂation for valve deployment with the pigtail catheter left
just before full balloon expansion and valve deployment. Fluoroscopic images imm
(E) posteroanterior, (F) left anterior oblique. Thin arrows highlight the pigtail cath
the waist of the Edwards-SAPIEN-XT TAV within the stentless (no radio-opaque mslow balloon inflation technique might be useful in these cases,especially when TEE images are suboptimal to guide valve
positioning and implantation. However, further studies with a
larger number of patients are needed to confirm the safety and
efficacy of this treatment for patients with stentless valve
dysfunction.
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APPENDIX
chnique
-expandable Edwards-SAPIEN-XT prosthesis within the failed stentless (no radio-
the pigtail catheter before valve deployment was considered the optimal posi-
e just until the TAV was half-deployed. (D) The pigtail catheter was pulled back
ely after successful transfemoral transcatheter aortic valve-in-valve implantation:
hick arrows the nose cone of the NovaFlex Delivery System, and arrowheads
xenograft. For better appreciation, see also Online Videos 4, 5, 6, and 7.ion Te
alloon
bove
in plac
ediat
eter, tFor accompanying videos, please see the online version of this article.
